AU2019375409A1 - Dosing regimen of anti-TIGIT antibody for treatment of cancer - Google Patents

Dosing regimen of anti-TIGIT antibody for treatment of cancer Download PDF

Info

Publication number
AU2019375409A1
AU2019375409A1 AU2019375409A AU2019375409A AU2019375409A1 AU 2019375409 A1 AU2019375409 A1 AU 2019375409A1 AU 2019375409 A AU2019375409 A AU 2019375409A AU 2019375409 A AU2019375409 A AU 2019375409A AU 2019375409 A1 AU2019375409 A1 AU 2019375409A1
Authority
AU
Australia
Prior art keywords
antibody
light chain
heavy chain
seq
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019375409A
Other languages
English (en)
Inventor
Mingmei CAI
Elliot K. Chartash
Jane Anne HEALY
Mallika LALA
Tommy Ruosi LI
Kapil Mayawala
Raluca Andreia PREDOIU
Sybil M. G. Williams
Zhen ZENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of AU2019375409A1 publication Critical patent/AU2019375409A1/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Amend patent request/document other than specification (104) Assignors: MERCK SHARP & DOHME CORP.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2019375409A 2018-11-05 2019-11-04 Dosing regimen of anti-TIGIT antibody for treatment of cancer Abandoned AU2019375409A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
US62/755,805 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2019375409A1 true AU2019375409A1 (en) 2021-05-27

Family

ID=70611082

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019375409A Abandoned AU2019375409A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-TIGIT antibody for treatment of cancer

Country Status (10)

Country Link
US (1) US20210403557A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877418A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512851A (cg-RX-API-DMAC7.html)
KR (1) KR20210091209A (cg-RX-API-DMAC7.html)
CN (1) CN113302204A (cg-RX-API-DMAC7.html)
AU (1) AU2019375409A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008582A8 (cg-RX-API-DMAC7.html)
CA (1) CA3118964A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005236A (cg-RX-API-DMAC7.html)
WO (1) WO2020096915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2021257124A1 (en) * 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4219553A4 (en) * 2020-09-22 2024-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-TIGIT ANTIBODIES AND DUAL ANTIBODIES AND THEIR APPLICATION
JP2024532744A (ja) * 2021-08-10 2024-09-10 メルク・シャープ・アンド・ドーム・エルエルシー T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
CA2957722C (en) * 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
SG10202007764TA (en) * 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US20210363243A1 (en) * 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody

Also Published As

Publication number Publication date
KR20210091209A (ko) 2021-07-21
MX2021005236A (es) 2021-06-18
JP2022512851A (ja) 2022-02-07
EP3877418A4 (en) 2022-08-17
WO2020096915A1 (en) 2020-05-14
BR112021008582A2 (pt) 2021-08-10
JP2025004212A (ja) 2025-01-14
BR112021008582A8 (pt) 2023-02-07
CN113302204A (zh) 2021-08-24
US20210403557A1 (en) 2021-12-30
EP3877418A1 (en) 2021-09-15
CA3118964A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
US12534530B2 (en) Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US20210403557A1 (en) Dosing regimen of anti-tigit antibody for treatment of cancer
AU2020210145A1 (en) Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer
JP7470105B2 (ja) 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd-1アンタゴニストおよびlag3アンタゴニストの組み合わせ
CN107810013A (zh) 用于治疗癌症的pd‑1拮抗剂和艾立布林的组合
CN106456753A (zh) 用于治疗癌症的pd‑1拮抗剂和ido1抑制剂的组合
AU2015264528A1 (en) Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
US20180044418A1 (en) Combination of a pd-1 antagonist and vorinostat for treating cancer
US20210347889A1 (en) Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
EP4213846A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
RU2833669C2 (ru) Режим введения антитела к tigit для лечения рака
WO2025128499A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN121038812A (zh) 用抗btla作为联合疗法治疗实体瘤的组合和方法
HK40010365A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application